Cold Spring Biotech Showcases Blood-Based pTau217 Test for Early Alzheimer's Detection

Cold Spring Biotech Corp. highlighted the clinical potential of its pTau217 blood test for the early detection of Alzheimer's disease during a featured presentation at BIO Asia–Taiwan. The presentation demonstrated how this highly accurate, minimally invasive blood test can support large-scale screening, facilitate earlier diagnosis, and improve treatment monitoring, thereby enabling patients to access timely interventions at an earlier stage of the disease.

Dr. Yu-Ming Shiao, General Manager of Cold Spring Biotech, delivered a presentation titled "Enabling Early Alzheimer's Disease Detection at Scale," highlighting the latest advances in blood-based pTau217 testing and its expanding role in Alzheimer's disease diagnosis and clinical management. During the presentation, Dr. Shiao referenced findings from the Alzheimer's Association indicating that diagnosing Alzheimer's disease during the mild cognitive impairment (MCI) stage could substantially reduce healthcare expenditures.

Statistical models estimate potential savings of up to US$7.9 trillion, underscoring the significant clinical and economic value of earlier diagnosis and intervention.Growing clinical evidence suggests that pTau217 blood test can detect Alzheimer's disease-related pathology 5 to 20 years before the onset of clinical symptoms. Early identification of at-risk individuals also creates opportunities for lifestyle interventions that may delay symptom onset by 2 to 5 years, reinforcing the importance of accessible and scalable early screening.Cold Spring Biotech's pTau217 blood test is powered by the Quanterix Simoa® ultra-sensitive detection platform, which delivers analytical sensitivity more than 1,000 times that of conventional immunoassays. The assay has demonstrated over 90% diagnostic accuracy, while pTau217 has been extensively studied in more than 4,000 peer-reviewed publications, supporting its growing adoption as a reliable blood biomarker for Alzheimer's disease.Clinical studies have demonstrated that the pTau217 blood test offers excellent predictive performance for Alzheimer's disease pathology, with diagnostic accuracy approaching that of current clinical reference methods.

Compared with positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) testing, the pTau217 blood test provides a lower-cost, non-invasive, and more patient-friendly alternative that is well suited for large-scale screening, with the potential to reduce both patient burden and healthcare costs.

Beyond early diagnosis, the pTau217 blood test has also emerged as a clinically meaningful biomarker for monitoring therapeutic response to disease-modifying therapies for Alzheimer's disease. During the presentation, Dr. Shiao shared clinical data from patients treated with Leqembi®, which showed that pTau217 blood levels declined significantly following treatment and correlated with reductions in amyloid plaque burden.

These findings further support the use of pTau217 for evaluating and monitoring treatment response."Blood-based biomarkers are transforming the future of Alzheimer's disease diagnosis and management," said Dr. Shiao. "Compared with conventional diagnostic approaches, the pTau217 blood test offers greater accessibility, lower cost, and greater patient acceptance, making large-scale population screening increasingly feasible. As precision diagnostics continue to advance, we believe blood biomarker testing will play a critical role in enabling earlier intervention and supporting a shift from symptom-based care toward precision prevention and treatment."